Entasis dips in first trading day after $75M IPO

Spun out of AstraZeneca plc (LSE:AZN; NYSE:AZN) in 2015, Entasis is developing a pipeline of antibiotics. It hopes to begin a Phase III trial in 1Q19 of ETX2514SUL, a fixed-dose, injectable combination therapy to treat multidrug resistant infections caused by Acinetobacter baumannii.